Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 220

1.

Inhibition of human N- and T-type calcium channels by an ortho-phenoxyanilide derivative, MONIRO-1.

McArthur JR, Motin L, Gleeson EC, Spiller S, Lewis RJ, Duggan PJ, Tuck KL, Adams DJ.

Br J Pharmacol. 2017 Jun 13. doi: 10.1111/bph.13910. [Epub ahead of print]

PMID:
28608537
2.

Radiation-associated plasmacytoma following catheter ablation for atrial fibrillation.

Chow J, Trotter T, Duggan P, Wilton SB.

HeartRhythm Case Rep. 2016 Dec 31;3(1):7-9. doi: 10.1016/j.hrcr.2016.10.003. eCollection 2017 Jan. No abstract available.

3.

Comprehensive pharmacological profiling of neurofibromatosis cell lines.

Guo J, Grovola MR, Xie H, Coggins GE, Duggan P, Hasan R, Huang J, Lin DW, Song C, Witek GM, Berritt S, Schultz DC, Field J.

Am J Cancer Res. 2017 Apr 1;7(4):923-934. eCollection 2017.

4.

Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?

Lee H, Duggan P, Neri P, Tay J, Bahlis NJ, Jimenez-Zepeda VH.

Bone Marrow Transplant. 2017 Jun;52(6):915-917. doi: 10.1038/bmt.2017.28. Epub 2017 Mar 13. No abstract available.

PMID:
28287637
5.

Controlled surface plasmon enhanced fluorescence from 1D gold gratings via azimuth rotations.

Byrne D, Duggan P, McDonagh C.

Methods Appl Fluoresc. 2017 Mar 1;5(1):015004. doi: 10.1088/2050-6120/aa5d2c.

PMID:
28248647
6.

Renal Papillary and Calyceal Lesions at CT Urography: Genitourinary Imaging.

Kawamoto S, Duggan P, Sheth S, Miyamoto H, Kazi ZN, Fishman EK.

Radiographics. 2017 Jan-Feb;37(1):358-359. doi: 10.1148/rg.2017160089. Review. No abstract available.

PMID:
28076022
7.

Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.

Jimenez-Zepeda VH, Duggan P, Neri P, Tay J, Bahlis NJ.

Ann Hematol. 2017 Mar;96(3):431-439. doi: 10.1007/s00277-016-2901-x. Epub 2017 Jan 10.

PMID:
28074255
8.

Molecular Markers for Pyrethrin Autoxidation in Stored Pyrethrum Crop: Analysis and Structure Determination.

Freemont JA, Littler SW, Hutt OE, Mauger S, Meyer AG, Winkler DA, Kerr MG, Ryan JH, Cole HF, Duggan PJ.

J Agric Food Chem. 2016 Sep 28;64(38):7134-41. doi: 10.1021/acs.jafc.6b02959. Epub 2016 Sep 19.

PMID:
27599033
9.

Case of coccidioidomycosis in Ireland.

Duggan PT, Deegan AP, McDonnell TJ.

BMJ Case Rep. 2016 Aug 11;2016. pii: bcr2016215898. doi: 10.1136/bcr-2016-215898.

PMID:
27516109
10.

Revised International Staging System Applied to Real World Multiple Myeloma Patients.

Jimenez-Zepeda VH, Duggan P, Neri P, Rashid-Kolvear F, Tay J, Bahlis NJ.

Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):511-518. doi: 10.1016/j.clml.2016.06.001. Epub 2016 Jun 8.

PMID:
27425179
11.

Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.

Jimenez-Zepeda VH, Duggan P, Neri P, Bahlis NJ.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e79-84. doi: 10.1016/j.clml.2016.03.005. Epub 2016 Mar 29.

PMID:
27101985
12.

Bioactive Mimetics of Conotoxins and other Venom Peptides.

Duggan PJ, Tuck KL.

Toxins (Basel). 2015 Oct 16;7(10):4175-98. doi: 10.3390/toxins7104175. Review.

13.

Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant.

Jimenez-Zepeda VH, Duggan P, Neri P, Chaudhry A, Murray K, Culham M, Luider J, Fourie T, Rashid-Kolvear F, Bahlis NJ.

Leuk Lymphoma. 2016;57(4):973-6. doi: 10.3109/10428194.2015.1085534. Epub 2015 Oct 8. No abstract available.

PMID:
26450458
14.

Co-existent B-cell and plasma cell neoplasms: a case series providing novel clinical insight.

Jamani K, Duggan P, Neri P, Bahlis N, Jimenez-Zepeda VH.

Leuk Lymphoma. 2016;57(3):557-62. doi: 10.3109/10428194.2015.1061189. Epub 2015 Jul 7.

PMID:
26065437
15.

Inhibition of N-type calcium channels by fluorophenoxyanilide derivatives.

Gleeson EC, Graham JE, Spiller S, Vetter I, Lewis RJ, Duggan PJ, Tuck KL.

Mar Drugs. 2015 Apr 13;13(4):2030-45. doi: 10.3390/md13042030.

16.

How was the intern year?: self and clinical assessment of four cohorts, from two medical curricula.

Laven G, Keefe D, Duggan P, Tonkin A.

BMC Med Educ. 2014 Jun 24;14:123. doi: 10.1186/1472-6920-14-123.

17.

Naturally occurring polyphenolic inhibitors of amyloid beta aggregation.

Churches QI, Caine J, Cavanagh K, Epa VC, Waddington L, Tranberg CE, Meyer AG, Varghese JN, Streltsov V, Duggan PJ.

Bioorg Med Chem Lett. 2014 Jul 15;24(14):3108-12. doi: 10.1016/j.bmcl.2014.05.008. Epub 2014 May 13.

PMID:
24878198
18.

An iterative in silico and modular synthetic approach to aqueous soluble tercyclic α-helix mimetics.

Lim Z, Duggan PJ, Meyer AG, Tuck KL.

Org Biomol Chem. 2014 Jul 7;12(25):4432-44. doi: 10.1039/c4ob00647j.

PMID:
24847981
19.

Fludarabine metabolite level on day zero does not affect outcomes of hematopoietic cell transplantation in patients with normal renal function.

Griffiths CD, Ng ES, Kangarloo SB, Williamson TS, Chaudhry MA, Booker R, Duggan P, Yue P, Savoie L, Brown C, Cox-Kennett N, Russell JA, Daly A, Storek J.

Bone Marrow Transplant. 2014 Apr;49(4):589-91. doi: 10.1038/bmt.2013.234. Epub 2014 Jan 27. No abstract available.

PMID:
24464143
20.

Assessment of the early regenerative therapeutic response in graft versus host disease using high definition technology with virtual i-Scan chromoendoscopy.

Iacucci M, Daly A, Chaudhry A, Duggan P, Gui X, Love J, Ghosh S.

Endoscopy. 2013;45 Suppl 2 UCTN:E389-90. doi: 10.1055/s-0033-1344823. Epub 2013 Nov 27. No abstract available.

PMID:
24285063

Supplemental Content

Loading ...
Support Center